Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Erlotinib, Gemcitabine, and Cisplatin in Metastatic Pancreatic Cancer
NCT00922896Phase 2Completed
- Sponsor
- Gyeongsang National University Hospital
- Start
- Jun 2009
- Primary completion
- Aug 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of erlotinib in pancreatic cancer (PC), sponsored by Gyeongsang National University Hospital. Primary endpoint: Objective Response Rate at 6 weeks. Started Jun 2009; status: completed.
02
Drugs
erlotinib
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on NCT00922896.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00922896.